31. Jan 2025 News Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
16. Jul 2024 News CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab